New eye injection for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new eye injection called GB10 for people with wet AMD, a condition that causes rapid vision loss. The goal is to see if it is safe and works to improve or stabilize vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have 'wet' age-related macular degeneration (AMD) with active leakage or fluid.
- You may be new to treatment or have had your last anti-VEGF injection more than 3 months ago.
- Your vision in the study eye should be between 20/32 and 20/320 (able to read large letters).
- The affected eye must not have serious other conditions like glaucoma or prior eye surgery (except cataract surgery >3 months ago).
- You must not have had a stroke or heart attack in the last 6 months.
- If you are pregnant or nursing, you cannot participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests a new eye injection (called QL1207H) against aflibercept, a standard treatment for wet macular degeneration. The goal is to see if the new drug is as effective in improving vision and reducing fluid in the eye.
This trial tests a new eye injection (GenSci148) for people with wet age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. The injection may help reduce swelling and abnormal blood vessel growth in the retina, which can improve or stabilise vision.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.